Metastatic Soft Tissue Sarcoma Recruiting Phase 2 Trials for Cabozantinib (DB08875)

Also known as: Metastatic Soft-tissue Sarcoma / Metastatic Soft-Tissue Sarcomas

IndicationStatusPhase
DBCOND0055864 (Metastatic Soft Tissue Sarcoma)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04551430Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue SarcomaTreatment
NCT04200443Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue SarcomaTreatment